Beneficial effects of statins on endothelial dysfunction and vascular stiffness

Current Vascular Pharmacology

Volumn 5, Issue 3, 2007, Pages 227-237

  Dilaveris, Polychronis ^a,b   Giannopoulos, Georgios ^a   Riga, Maria ^a   Synetos, Andreas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Arterial; Endothelial dysfunction; Statins; Stiffness.; Vascular

Indexed keywords

ATORVASTATIN; CAVEOLIN; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; FLUINDOSTATIN; HEAT SHOCK PROTEIN 90; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; RAC1 PROTEIN; SIMVASTATIN; THIOREDOXIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; SHEAR STRESS; ANIMAL; ARTERY; CARDIOVASCULAR DISEASE; DRUG EFFECT; ELASTICITY; PATHOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; ARTERIES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; ELASTICITY; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 34547587360     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016107781024091     Document Type: Review

References (151)

1. Arnett DK, Evans GW, Riley WA. Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol 1994; 140: 669-82.
2. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
3. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
4. Libby P. The Vascular Biology of Atherosclerosis-The intima. In Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 6th Edition. Philadelphia: Saunders; 2001: 995.
5. Gonzalez MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003; 115(Suppl 8A): 99S-106S.
6. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado R. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
7. Yang Z, Ming XF. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res 2006; 4(1): 53-65.
8. Brevetti G, Martone VD, de Cristofaro T, Corado S, Silvestro A, DiDonato AM, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
9. Yang Z, Luscher TF. Vascular endothelium. In: Lanzer P, Topol EJ, eds. Pan vascular medicine. Berlin - Heidelberg - New York: Springer. 2002; 190-204.
10. Cooke JP, Tsao PS. Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994; 14: 753-9.
11. Baldwin A. The transcription factor NK-6B and human disease. J Clin Invest 2001; 107: 3-6.
12. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
13. Bugiardini R, Manfrini O, Pizzi C, Fontana F, Morgagni G. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms. Circulation 2004; 109: 2518-23.
14. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-III32.
15. Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-88.
16. Anderson RG. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 1993; 90: 10909-13.
17. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998; 392: 821-4.
18. Ueda S, Matsuoka H, Miyazaki H, Usui M, Okuda S, Imaizumi T. Tetrahydrobiopterin restores endothelial function in long-term smokers. J Am Coll Cardiol 2000; 35: 71-5.
19. Nickening G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. Circulation 2002, 105: 393-6
20. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
21. Tsimikas S, Witztum JL. Measuring circulating oxidized low-density lipoprotehn to evaluate coronary risk. Circulation 2001; 103: 1930-2.
22. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005; 85: 9-23. (Erratum in: Lab Invest 2005; 85: 942.)
23. Hwang J, Ing MH, Salazar A, Laseque P, Griendling K, Navab M, et al. Pulsatile vs. oscillatory shear stress regulates NADPH oxidase subunit expression - implication for native LDL oxidation. Circ Res 2003; 93: 1225-32.
24. Makek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 1999; 282: 2035-42.
25. Resnick N, Yahav H, Shay-Salit A, Shushy A, Schubert S, Ziberman LC, et al. Fluid shear stress and the vascular endothelium: for better and for worse. Prog Biophys Mol Biol 2003; 81: 177-99.
26. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258: 1183-6.
27. Ikeda Y, Handa M, Kawano K, Kamata T, Murata M, Araki Y, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest 1991; 87: 1234-40.
28. Bots ML, Westerink J, Rabelink TJ, de Koning EJP. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2006; 26: 363-8.
29. Eskurza I, Seals DR, DeSouza CA, Tanaka H. Pharmacologic vs. flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol 2001; 88: 1067-9.
30. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-10.
31. O'Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002; 15: 426-44.
32. Franklin S, Gustin W. IV, Wong N, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham heart study. Circulation 1997; 96: 308-15.
33. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-9.
34. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux X, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-41.
35. Boutouyrie P, Tropeano A, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 9: 10-5.
36. Pearson A, Guo R, Orsinelli D, Binkley P, Pasierski T. Transesophageal echocardiographic assessment of the effects of age, gender and hypertension on thoracic aortic wall size, thickness and stiffness. Am Heart J 1994; 128: 344-51.
37. Tanaka H, Dinenno F, Monahan K, Clevenger C, DeSouza C, Seals D. Aging, habitual exercise and dynamic arterial compliance. Circulation 2000; 102: 1270-5.
38. Soma J, Aakhus S, Angelsen BA, Skjaerpe T. Influence of body size and left ventricular ejection dynamics on total arterial compliance determined using Doppler echocardiography and subclavian artery pulse tracing in healthy humans. Blood Press 1998; 7: 239-46.
39. Stefanadis C, Wooley C, Bush C, Kolibash AJ, Boudaulas H. Aortic distensibility abnormalities in coronary artery disease. Am J Cardiol 1987; 59: 1300-4.
40. Blacher J, London GM, Safar ME, Mourad A. Influence of age and end-renal disease on the stiffness of carotid wall material in hypertension. Hypertension 1999; 17: 237-44.
41. Salooma V, Riley W, Klark JD, Narda C, Folsom AR. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes: the ARIC study. Circulation 1995; 91: 1432-43.
42. Pitsavos C, Toutouzas K, Dernellis J, Skoumbourdis E, Stefanadis C, Toutouzas P. Aortic stiffness in young patients with heterozygous familial hypercholesterolemia. Am Heart J 1998; 135: 604-8.
43. Papaioannou TG, Mathioulakis D, Nanas J, Tsangaris S, Stamatelopoulos S, Moulopoulos S. Arterial compliance is a main variable determining the effectiveness of intra-aortic balloon counterpulsation: quantitative data from an in vitro study. Med Eng Physics 2002; 24: 279-84.
44. Laurent S, Boutouyrie P, Lacolley P. Structural and Genetic Bases of Arterial Stiffness. Hypertension 2005; 45: 1050-5.
45. Papaioannou TG, Karatzi K, Karatzis E, Papamichael C, Lekakis JP. Acute Effects of Caffeine on Arterial Stiffness, Wave Reflections, and Central Aortic Pressures. Am J Hypertens 2005; 18: 129-36.
46. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714-20.
47. Kass DA. Ventricular Arterial Stiffening. Integrating the Pathophysiology. Hypertension 2005; 46: 185-93.
48. Pannier BM, Avolio AP, Hoeks A, Mancia G, Takazawa K. Methods and devices for measuring arterial compliance in humans. Am J Hypertens 2002; 15: 743-53.
49. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26: 485-90.
50. Laurent S, Caviezel B, Beck L, Girerd X, Billaud E, Boutouyrie P, et al. Carotid artery distensibility and distending pressure in hypertensive humans. Hypertension 1994; 23(part 2): 878-83.
51. Nichols WW, O'Rourke MF. Aging, high blood pressure and disease in humans. In: Nichols WW O'Rourke MF, eds. McDonald's Blood Flow in Arteries. Theoretic, Experimental and Clinical Principles, Third Ed. London: Edward Arnold; 1990: 398-420.
52. Vogel RA, Corretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77: 37-40.
53. Perticone F, Ceravolo R, Maio R, Cloro C, Candigliota M, Scozzafava A, et al. Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients. Atherosclerosis 2000; 152: 511-8.
54. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular effects of statin therapy. Curr Med Res Opin 2003; 19(6): 540-6.
55. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 3-5.
56. Landmesser U, Engberding N, Bahlmann F, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, LV function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110:1933-9.
57. Di Napoli P, Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001; 51: 283-93.
58. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, et al. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolemic subjects. Br J Clin Pharmacol 2002; 54: 395-9.
59. Beckman JA, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, et al. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ Res 2004; 95: 217-23.
60. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin vs. ezetimibe pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356-63.
61. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Roessig L, Heeschen C, Dimmeler S, et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006; 27: 1182-90.
62. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990; 86: 228-34.
63. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
64. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Canon RO III. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation 1994; 90: 35-41.
65. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990; 86: 75-9.
66. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H. LPC in oxidized LDL elicits vasocontraction and inhibits endothelium-dependent relaxation. Am J Physiol 1994; 297: H2441-9.
67. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-500.
68. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93.
69. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
70. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
71. Tamai O, Matsuoka H, Itabe H, Wagda Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
72. Hürlimann D, Ruschitzka F, Lüscher TF. The relationship between the endothelium and the vessel wall. Eur Heart J Suppl 2002; 4(Supplement A): A1-A7
73. Keaney JF Jr, Guo Y, Cunningham D, Swaery GT, Xu A, Vita JA. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 1996; 98: 386-94.
74. Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996; 93: 1740-6.
75. Mehta A, Yang B, Khan S, Hendricks JB, Stephen C, Mehta JL. Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation: role of P-selectin. Arterioscler Thromb Vasc Biol 1995; 15: 2076-83.
76. Yanagisawa M, Kunihara H, Kimura S Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5.
77. Endres M, Laufs U. Effects of statins on endothelium and signalling mechanisms. Stroke 2004; 35; 2708-11.
78. Martinez-Gonzalez J, Raposo B, Rodriguez C, Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibition prevents endothelial NO synthase downregulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 2001; 21: 804-9.
79. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19: 7289-304.
80. Edidin M. Lipid microdomains in cell surface membranes. Curr Opin Struct Biol 1997; 7: 528-32.
81. Feron O, Dessy C, Moniotte S, Desager JP, Balligand JL. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999; 103: 897-905.
82. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxymethylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-8.
83. Pelat M, Dessy C, Massion P, Desager JP, Feron O, Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation 2003; 107: 2480-6.
84. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function role of microdomains and oxidative stress. Circulation 2004; 109: II-34 - II-41.
85. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hosikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997; 386: 73-7.
86. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1. Arterioscler Thromb Vasc Biol 2000; 20: 1116-22.
87. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL. LOX-1 mediates oxidized low-density lipoptotein induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003; 107: 612-7.
88. Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001; 52: 130-5.
89. Wassmann S, Laufs U, Baümer AT, Mueller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPAse. Mol Pharmacol 2001; 59: 646-54.
90. Gorlach A, Brandes RP, Nguyen K, Amidi M, Deghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000; 87: 26-32.
91. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins. Circulation 2004; 110: 856-61.
92. Didier C, Kerblat I, Drouet C, Favier A, Beani JC, Richard MJ. Induction of thioredoxin by ultraviolet-A radiation prevents oxidative-mediated cell death in human skin fibroblasts. Free Radic Biol Med 2001; 31: 585-98.
93. Shioji K, Kishimoto C, Nakamura H, Masutani H, Yuan Z, Oka S, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation 2002; 106: 1403-9.
94. Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
95. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl(HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-5.
96. Nishimatsu H, Suzuki E, Satonaka H, Takeda R, Omata M, Fujita T, et al. Endothelial dysfunction and hypercontractility of vascular myocytes are ameliorated by fluvastatin in obese Zucker rats. Am J Physiol 2005; 288: H1770-6.
97. Perings SM, Grubert N, Kleinbongard P, Reinecke P, Schulz R, Hermsen D, et al. Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia. J Cardiovasc Pharmacol 2004; 43: 183-90.
98. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-14.
99. Shiga N, Hirano K, Hirano M, Nishimura J, Nawata H, Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005; 96: 1014-21.
100. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
101. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-5.
102. Gonzalez-Fernandez F, Jimenez A, Lopez-Blaya A, Velasco S, Arriero MM, Celdran A, et al. Cerivastatin prevents tumour necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins. Atherosclerosis 2001; 155: 61-70.
103. Laufs U, Endres M, Custodis F, Gertz K, NickenigG, Liao JK, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation 2000; 102: 3104-10.
104. Dimmeler S, Fisslthaler B, Fleming I, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells via Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
105. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
106. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Leer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
107. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-7.
108. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-77.
109. Boodbwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S, et al. High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 2006; 114: 402-8.
110. Nagoshi T, Matsui T, Aoyama T, Leri A, Anversa P, Li L, et al. PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury. J Clin Invest 2005; 115: 2128-38.
111. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
112. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. The Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5.
113. Stefanadis C, Toutouzas K, Vavuranakis M, Tsiamis E, Tousoulis D, Panagiotakos DB, et al. Statin treatment is associated with reduced thermal heterogeneity in human atherosclerotic plaques. Eur Heart J 2002; 23: 1664-9.
114. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
115. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme. A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5.
116. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
117. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. Br Med J 1996; 312: 1061-5.
118. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. for the Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
119. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000; 343: 1139-47.
120. Venugopal SK, Devaraj S, Yuhanna I, Shaul P, Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-41.
121. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-9.
122. Seljeflot I, Tonstad S, Hjermann I, Arnesen H. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002; 162: 179-85.
123. Wiklund O, Mattsson-Hulte'n L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002; 251: 338-47.
124. Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med 2000; 48: 183-9.
125. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Pitsavos C, Vlachopoulos C, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005; 178: 359-63.
126. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns Chr, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med 2001; 7: 687-92.
127. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
128. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998; 92:362-7.
129. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231-6.
130. Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002; 106: 3009-17.
131. Strauer BE, Brehm M, Zeus T, Kostering M, Hernandez A, Sorg RV, et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 2002; 106: 1913-8.
132. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7.
133. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
134. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001; 108: 391-7.
135. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 2001; 108: 399-405.
136. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, et al. Statin therapy accelerates re-endothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-24.
137. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rössig L, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92: 1049-55.
138. Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via "imported" nitric oxide synthase activity. Circulation 2005; 111: 1114-20.
139. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003; 9: 1370-6.
140. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46: 1693-701.
141. Failla M, Grappiolo A, Emanuelli G, Vitale G, Fraschini N, Bigoni M. et al. Sympathetic tone restrains arterial distensibility of healthy and atherosclerotic subjects. J Hypertens 1999; 17: 1117-1123.
142. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle sympathetic nerve activity and large artery mechanical vessel wall properties in renal transplant patients. J Hypertens 2002; 20: 501-8.
143. McVeigh GE, Bratteli CW, Morgan DJ, Alinder CM, Glasser SP, Finkelstein SM, et al. Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis: aging and arterial compliance. Hypertension 1999; 33: 1392-1398.
144. Kontopoulos AG, Athyros VG, Pehlivanidis AN, Demitriadis DS, Papageorgiou AA, Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolemic patients. Curr Med Res Opin 2003; 19: 22-7.
145. Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001; 14: 1096-8.
146. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance but not in the aorta. Atherosclerosis 2001; 158: 207-14.
147. Shinohara K, Shoji T, Kimoto E, Yokoyama H, Fujiwara S, Hatsuda S, et al. Effect of atorvastatin on regional arterial stiffness in patients with Type 2 diabetes mellitus. J Atheroscler Thromb 2005; 12: 205-10.
148. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
149. Van Doomum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1571-5.
150. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17: 1513-7.
151. Ceriello A, Assaloni R, Da Ros R, Maier A, Piconi L, Quagliaro L, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-24.